These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 27146381)

  • 21. [Systemic sclerosis - diagnosis and classification].
    Genth E; Krieg T
    Z Rheumatol; 2006 Jul; 65(4):268-74. PubMed ID: 16804700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment.
    Villela R; Yuen SY; Pope JE; Baron M;
    Arthritis Rheum; 2008 May; 59(5):706-13. PubMed ID: 18438906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy.
    Henry TW; Mendoza FA; Jimenez SA
    Autoimmun Rev; 2019 Nov; 18(11):102396. PubMed ID: 31520794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical and translational research to discover potentially effective antifibrotic therapies in systemic sclerosis.
    Jordan S; Chung J; Distler O
    Curr Opin Rheumatol; 2013 Nov; 25(6):679-85. PubMed ID: 24047603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
    Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis.
    Farina N; Campochiaro C; Lescoat A; Benanti G; De Luca G; Khanna D; Dagna L; Matucci-Cerinic M
    Expert Rev Clin Immunol; 2023; 19(9):1131-1142. PubMed ID: 37366065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic mechanisms: An emerging role in pathogenesis and its therapeutic potential in systemic sclerosis.
    Luo Y; Wang Y; Shu Y; Lu Q; Xiao R
    Int J Biochem Cell Biol; 2015 Oct; 67():92-100. PubMed ID: 26043891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials.
    Roofeh D; Lescoat A; Khanna D
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):455-466. PubMed ID: 33054463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early systemic sclerosis-opportunities for treatment.
    Sakkas LI; Simopoulou T; Katsiari C; Bogdanos D; Chikanza IC
    Clin Rheumatol; 2015 Aug; 34(8):1327-31. PubMed ID: 25711876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Existing and novel biomarkers for precision medicine in systemic sclerosis.
    Wermuth PJ; Piera-Velazquez S; Rosenbloom J; Jimenez SA
    Nat Rev Rheumatol; 2018 Jul; 14(7):421-432. PubMed ID: 29789665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging targets of disease-modifying therapy for systemic sclerosis.
    Volkmann ER; Varga J
    Nat Rev Rheumatol; 2019 Apr; 15(4):208-224. PubMed ID: 30796362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis.
    Lin AT; Clements PJ; Furst DE
    Rheum Dis Clin North Am; 2003 May; 29(2):409-26. PubMed ID: 12841302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research.
    Avouac J; Kowal-Bielecka O; Landewe R; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 May; 68(5):629-34. PubMed ID: 18957486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis.
    Khanna D; Furst DE; Wong WK; Tsevat J; Clements PJ; Park GS; Postlethwaite AE; Ahmed M; Ginsburg S; Hays RD;
    Qual Life Res; 2007 Aug; 16(6):1083-92. PubMed ID: 17404896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic sclerosis: markers and targeted treatments.
    Cutolo M; Sulli A; Pizzorni C; Paolino S; Smith V
    Acta Reumatol Port; 2016; 41(1):18-25. PubMed ID: 27115104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic sclerosis - continuing progress in developing clinical measures of response.
    Furst D; Khanna D; Matucci-Cerinic M; Clements P; Steen V; Pope J; Merkel P; Foeldvari I; Seibold J; Pittrow D; Polisson R; Strand V
    J Rheumatol; 2007 May; 34(5):1194-200. PubMed ID: 17477486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
    Khanna D; Furst DE; Clements PJ; Park GS; Hays RD; Yoon J; Korn JH; Merkel PA; Rothfield N; Wigley FM; Moreland LW; Silver R; Steen VD; Weisman M; Mayes MD; Collier DH; Medsger TA; Seibold JR; ;
    J Rheumatol; 2005 May; 32(5):832-40. PubMed ID: 15868618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic sclerosis: Advances towards stratified medicine.
    Quinlivan A; Ross L; Proudman S
    Best Pract Res Clin Rheumatol; 2020 Feb; 34(1):101469. PubMed ID: 31973938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.
    Lescoat A; Varga J; Matucci-Cerinic M; Khanna D
    Expert Opin Investig Drugs; 2021 Jun; 30(6):635-652. PubMed ID: 33909517
    [No Abstract]   [Full Text] [Related]  

  • 40. Use of biologics and other novel therapies for the treatment of systemic sclerosis.
    Bruni C; Praino E; Allanore Y; Distler O; Gabrielli A; Iannone F; Matucci-Cerinic M
    Expert Rev Clin Immunol; 2017 May; 13(5):469-482. PubMed ID: 27899043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.